Menu
Search
|

Menu

Close
X

Novo Nordisk A/S NOVOB.CO (Copenhagen Stock Exchange)

321.80 DKK
+0.40 (+0.12%)
As of 4:36 AM EDT
Previous Close 321.40
Open 320.25
Volume 353,136
3m Avg Volume 2,450,971
Today’s High 324.55
Today’s Low 320.25
52 Week High 349.70
52 Week Low 265.15
Shares Outstanding (mil) 1,962.56
Market Capitalization (mil) 610,749.88
Forward P/E 20.21
Dividend (Yield %) 3.00 ( 2.44 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.50 Mean rating from 28 analysts

KEY STATS

Revenue (mm, DKK)
FY19
29,291
FY18
111,831
FY17
111,696
FY16
111,780
EPS (DKK)
FY19
4.362
FY18
15.921
FY17
15.377
FY16
14.960
*Note: Units in Millions of Danish Krone
**Note: Units in Danish Krone

KEY RATIOS

Price to Earnings (TTM)
vs sector
20.21
32.67
Price to Sales (TTM)
vs sector
5.35
7.92
Price to Book (MRQ)
vs sector
16.09
5.39
Price to Cash Flow (TTM)
vs sector
14.53
24.37
Total Debt to Equity (MRQ)
vs sector
3.47
14.56
LT Debt to Equity (MRQ)
vs sector
0.00
10.21
Return on Investment (TTM)
vs sector
76.65
14.49
Return on Equity (TTM)
vs sector
84.84
15.79

EXECUTIVE LEADERSHIP

Helge Lund
Independent Chairman of the Board, Since 2018
Salary: --
Bonus: --
Lars Fruergaard Joergensen
President, Chief Executive Officer, Since 2017
Salary: kr.10,700,000.00
Bonus: kr.8,900,000.00
Jeppe Christiansen
Vice Chairman of the Board, Since 2013
Salary: --
Bonus: --
Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President, Since 2018
Salary: kr.4,000,000.00
Bonus: kr.2,600,000.00
Maziar Doustdar
Executive Vice President, International Operations, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Novo Alle
BAGSVAERD     2880

Phone: +4544.448888

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

SPONSORED STORIES